<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842334</url>
  </required_header>
  <id_info>
    <org_study_id>2012P001707</org_study_id>
    <nct_id>NCT01842334</nct_id>
  </id_info>
  <brief_title>D-cycloserine (DCS) Pretreatment + CBT + Nicotine Replacement Therapy for Smoking Cessation (DCS)</brief_title>
  <acronym>DCS</acronym>
  <official_title>D-cycloserine (DCS) Pretreatment + Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Lung Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Compare the relative efficacy of ten weeks of once weekly 250 mg D-cycloserine (DCS) vs.
           placebo (both in conjunction with cognitive behavioral therapy (CBT) and nicotine
           replacement therapy (NRT) on reducing cigarette smoking in treatment-seeking
           nicotine-dependent outpatients.

        2. Compare the relative efficacy of ten weeks of once weekly 250 mg DCS vs. placebo on the
           process of extinction and the memory encoding process.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a Stage 1 pilot feasibility study at McLean Hospital to
      develop a medication to treat nicotine dependence. In a randomized, double-blind,
      placebo-controlled trial, 40 nicotine-dependent participants ages 18-65 will receive
      cognitive behavioral therapy (CBT) and nicotine replacement therapy (NRT) over a 10- week
      period, with half receiving D-cycloserine (DCS) pretreatment and half receiving placebo.
      Participants will receive either 250 mg DCS or placebo prior to weekly CBT sessions in
      addition to NRT over a 10-week treatment period. The investigators also aim to determine the
      effects of DCS on performance on neuropsychological tests. A 10-week treatment period will be
      followed by follow-up assessments including neuropsychological tests at 1 and 3 months
      post-treatment. Primary outcomes will include smoking as measured by carbon monoxide levels
      and self-report measurements.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    left institution protocol closed
  </why_stopped>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Cigarette Smoking in Treatment Seeking Nicotine Dependent Outpatients</measure>
    <time_frame>During Week 10</time_frame>
    <description>Cigarette smoking at 10 weeks as measured by carbon monoxide levels and self-report measurements.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>CBT administered to to both DCS and placebo group.</description>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>CBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement Therapy</intervention_name>
    <description>NRT administered to both DCS and placebo group.</description>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Age range 18-65 years; 2) DSM-IV diagnosis of nicotine dependence, based on the
        Structured Clinical Interview for DSM-IV (SCID) (First et al. 1996); 3) express a desire to
        quit cigarette smoking within the next 30 days; 4) smokes greater than or equal to 10
        cigarettes per day and less than or equal to 20 cigarettes per day; 5) an expired carbon
        monoxide (CO) determination greater than or equal to 10 ppm over ambient values; 6) for
        women of childbearing age, a negative pregnancy test at screening with agreement to use
        adequate contraception to prevent pregnancy and multiple subsequent pregnancy tests; 7)
        consent for us to communicate with their prescribing clinician; 8) furnish the names of 2
        locators, who would assist study staff in locating them during the study period; 9) live
        close enough to McLean Hospital to attend study visits; 10) plan to remain in the Boston
        area for the next 4 months; and 11) are willing and able to sign informed consent.

        Exclusion Criteria:

        1) Current diagnosis of other drug or alcohol dependence (other than nicotine); 2)
        significant cardiac disease; 3) current serious psychiatric illness or history of
        psychosis, schizophrenia, bipolar type I disorder (taking psychiatric medications, aside
        from wellbutrin, is not an exclusionary criterion); 4) have a current medical condition
        (including significant laboratory abnormalities, such as liver function tests &gt;5 times the
        upper limit of normal range) that could prevent regular study attendance; 5) have mental
        retardation or organic mental disorder; 6) exhibit acutely dangerous or suicidal behavior;
        7) are pregnant, nursing, or, if a woman of childbearing potential, not using a form of
        birth control judged by the Principal Investigator to be effective; 8) current NRT or other
        smoking cessation treatment;9) current CBT for smoking cessation; 10) current smokeless
        tobacco use; 11) inability to read or write in English;12) has epilepsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin P. Hill, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <results_first_submitted>July 9, 2018</results_first_submitted>
  <results_first_submitted_qc>July 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2018</results_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Kevin P. Hill, MD, MHS</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Nicotine Dependence</keyword>
  <keyword>Smoking Cessation</keyword>
  <keyword>D-cycloserine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT01842334/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>9 out of the 21 subject screened did not qualify for randomization. 6 of the subjects were no longer interested in participating after the screening visit, 2 did not return repeated phone calls by study staff and 1 subject did not qualify due to being on probation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>D-cycloserine</title>
          <description>250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
Cognitive Behavioral Therapy: CBT administered to to both DCS and placebo group.
Nicotine Replacement Therapy: NRT administered to both DCS and placebo group.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
Cognitive Behavioral Therapy: CBT administered to to both DCS and placebo group.
Nicotine Replacement Therapy: NRT administered to both DCS and placebo group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved away mid-study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>D-cycloserine</title>
          <description>250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
Cognitive Behavioral Therapy: CBT administered to to both DCS and placebo group.
Nicotine Replacement Therapy: NRT administered to both DCS and placebo group.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
Cognitive Behavioral Therapy: CBT administered to to both DCS and placebo group.
Nicotine Replacement Therapy: NRT administered to both DCS and placebo group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="6.96"/>
                    <measurement group_id="B2" value="39.57" spread="15.79"/>
                    <measurement group_id="B3" value="35.58" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cigs/Day</title>
          <units>cigarettes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.34" spread="2.18"/>
                    <measurement group_id="B2" value="12.87" spread="2.01"/>
                    <measurement group_id="B3" value="13.04" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cigarette Smoking in Treatment Seeking Nicotine Dependent Outpatients</title>
        <description>Cigarette smoking at 10 weeks as measured by carbon monoxide levels and self-report measurements.</description>
        <time_frame>During Week 10</time_frame>
        <population>Only the 5 completers of this study who made it to week 10 could have this measure analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
            <description>250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
Cognitive Behavioral Therapy: CBT administered to to both DCS and placebo group.
Nicotine Replacement Therapy: NRT administered to both DCS and placebo group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
Cognitive Behavioral Therapy: CBT administered to to both DCS and placebo group.
Nicotine Replacement Therapy: NRT administered to both DCS and placebo group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cigarette Smoking in Treatment Seeking Nicotine Dependent Outpatients</title>
          <description>Cigarette smoking at 10 weeks as measured by carbon monoxide levels and self-report measurements.</description>
          <population>Only the 5 completers of this study who made it to week 10 could have this measure analyzed.</population>
          <units>Cigarettes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="3.63"/>
                    <measurement group_id="O2" value="0.29" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse even data was collected from the baseline visit until the end of the study (14 weeks after baseline)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>D-cycloserine</title>
          <description>250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
Cognitive Behavioral Therapy: CBT administered to to both DCS and placebo group.
Nicotine Replacement Therapy: NRT administered to both DCS and placebo group.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
Cognitive Behavioral Therapy: CBT administered to to both DCS and placebo group.
Nicotine Replacement Therapy: NRT administered to both DCS and placebo group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea due to Nicotine Patch</sub_title>
                <description>Only 1 subject in the study reported nausea associated with the nicotine patch. The nicotine patch dosage was decreased from 21mg to 14mg by the PI following the procedure outlined in the protocol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to lack of sufficient funds/resources, the sample size for this study is not large enough to extract any conclusive results. The high number of subjects withdrawing from the study early also hinders any possible conclusions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kevin P Hill, Director of the Division of Addiction Psychiatry</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-1504</phone>
      <email>khill1@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

